EBI3 (IL-27 subunit) Monoclonal Antibody (DNT27), eBioscience™, Invitrogen™

Description

• Description: The monoclonal antibody DNT27 reacts with mouse Epstein-Barr Virus-induced gene 3 (EBI3)
• EBI3 is a 34 kDa soluble protein first identified in B cells that is upregulated after Epstein-Barr virus infection
• EBI3 can exist as a homodimer and also heterodimerizes with IL-27alpha (p28, IL-30) to form the cytokine IL-27
• IL-27 is produced most abundantly by dendritic cells and macrophages with some recent reports of expression in NKT cells
• Recently, a complex of EBI3 and the p35 subunit of IL-12, called IL-35, has been reported to be produced by regulatory T cells
• Applications Reported: This DNT27 antibody has been reported for use in immunoblotting (WB)
• Applications Tested: This DNT27 antibody has been tested by western blot of cell lysates prepared from mouse EBI3-transfected 293T cells and bone marrow-derived dendritic cells
• This can be used at less than or equal to 1-5 μg/mL
• It is recommended that the antibody be carefully titrated for optimal performance in the assay of interest
• Purity: Greater than 90%, as determined by SDS-PAGE
• Aggregation: Less than 10%, as determined by HPLC
• Filtration: 0.2 μm post-manufacturing filtered
• EBI3 (Epstein-Barr virus Induced-3) is a secreted glycoprotein of the hematopoietin receptor family
• It plays a critical regulatory role in the induction of Th2-type immune responses and the development of Th2-mediated tissue inflammation in vivo, which may be mediated through the control of iNKT cell function
• EBI3 dimerizes with p28 and p35 subunits of IL-12 to form new proteins IL-27 and IL-35, respectively
• IL-27 is an early product of activated antigen presenting cell that is produced upon TLR ligation
• It negatively regulates Th17 cell differentiation
• EBI3 is widely expressed and its expression in dendritic cell is transcriptionally regulated by TLR signaling via MyD88 and NF-kappaB during innate immune responses preceding cytokine driven Th cell development
• EBI3 signal inhibits delayed-type hypersensitivity responses by suppressing IL-17 production and inducing IL-10 hyperproduction
• EBI3 may play a novel role in controlling tumor metastasis via lung CD8+ T cells, and its deficiency is associated with a diminished production of Th2 cytokines which are known to regulate allergic airway inflammation in asthma
• Targeted deletion of EBI3 protects mice from lung metastasis.